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Introduction: Hormone replacement therapy can diminish hormone depletion-related complaints in
postmenopausal women, but is contraindicated for postmenopausal breast cancer (BC) patients. Re-
covery of menstruation after chemotherapy-induced amenorrhea in young hormone receptor-negative
BC patients however, is accepted. To determine the safety of this strategy, we investigated the effect of
recovery of menstruation on disease-free survival (DFS) and overall survival (OS) in young hormone
receptor-negative BC patients treated with (neo)adjuvant chemotherapy.
Methods: We selected 636 patients from a single-center cohort with early stage hormone receptor-
negative BC and under the age of 50 years when treated with chemotherapy. Sufficient data on course
of menstruation in medical records was retrospectively found for 397 patients, of whom 299 patients
(75%) had a recovery of menstruation after chemotherapy. We used Cox proportional hazards models to
estimate hazard ratios (HR) for the effect of recovery of menstruation on DFS and OS.
Results: Patients with recovery of menstruation after chemotherapy less frequently had lymph node
involvement at diagnosis (45% vs 66%, p ¼ 0.001). After a median follow-up of 6.7 years, the adjusted
hazard ratios were 1.45 (95% CI: 0.83e2.54) for DFS and 1.19 (95% CI: 0.71e1.98) for OS.
Conclusion: No significantly increased recurrence risk was found for hormone receptor-negative BC
patients with recovery of menstruation after chemotherapy. However, the outcome of the multivariable
model is not reassuring and a potentially increased recurrence risk cannot be excluded. The results need
to be validated in a larger prospective study for a more definitive answer.
© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Despite having a reputation of being a disease of the elderly,
cancer burden in young adults is quite substantial [1]. Approxi-
mately 20% of all invasive breast cancer (BC) patients are younger
than 50 years of age at the time of diagnosis [2]. To reduce the risk
of recurrent disease, a majority of young patients are treated with
chemotherapy [3]. Inmany of these young patients, menstruation istute, Department of Medical
dam, the Netherlands.
ooning).
ier Ltd. This is an open access articoften suppressed after the first or second cycle of chemotherapy
administration and irreversible in a substantial proportion of pa-
tients, depending on age and chemotherapy regimen [4,5].
Loss of ovarian activity can have a major impact on quality of
life; it results in infertility, often causes climacteric symptoms and
increases the risk of osteoporosis and possibly of cardiovascular
disease, cognitive impairment and even all-cause mortality [6].
Many of these hormone depletion-related symptoms and risks
could theoretically be reduced by hormone replacement therapy
(HRT) and interesting new strategies using luteinizing hormone-
releasing hormone analogues (LHRH-a) are emerging [7,8]. Of two
large randomized trials in patients with stage I to III BC that
investigated the risk of HRT on BC recurrence, one study reportedle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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decrease in hormone depletion-related symptoms [9]. Importantly
though, both studies were terminated prematurely because interim
analyses showed an increased risk of BC recurrence in the HRT
group [9,10]. Therefore, in general, HRT is contraindicated as
treatment of postmenopausal complaints for womenwith a history
of BC. Interestingly, subgroup analyses for estrogen receptor (ER)-
negative BC patients showed no significantly increased risk of BC
recurrence when treated with HRT (HR 1.9, 95% CI 0.4e9.6 [10] and
HR 1.15, 95% CI 0.73e1.80 [9]). However, these analyses were done
post-hoc, with relatively small subgroups [10] and no data
regarding potentially confounding factors were provided [9].
Therefore, whether there exists a potential risk from HRT use
among ER-negative BC patients with complaints of chemotherapy-
induced amenorrhea is still a matter of debate.
In clinical practice, recovery of menstruation after
chemotherapy-induced amenorrhea in young HR-negative BC pa-
tients is fully accepted. Moreover, prescription of HRT to young
triple-negative BC (TNBC) patients does happen in some clinics,
although data on safety is still lacking [11]. Since the safety of
accepting natural recovery of ovarian function in young hormone
receptor-negative BC patients treated with (neo)adjuvant chemo-
therapy is unclear, we investigated the effect of recovery of
menstruation on disease-free survival (DFS) and overall survival
(OS) in this patient population.
2. Methods
2.1. Study population
For this single-center consecutive cohort study, we selected BC
patients treated in the Erasmus MC Cancer Institute from our
institutional cancer registry database using the following inclusion
criteria: age at diagnosis <50 years, hormone receptor-negative BC
phenotype, BC diagnosed between 1990 and 2014, no evidence of
distant metastases at time of diagnosis, and treated with chemo-
therapy (either neoadjuvant or adjuvant). In accordance with the
Dutch breast cancer guidelines, hormone receptor negative
phenotype was defined as expression of ER and progesterone re-
ceptor (PR) less than 10% in immunohistochemical staining. The
HER2-status was defined to be positive if the immunohistochem-
ical staining was 3þ, or 2þ with a positive fluorescence in-situ
hybridization (FISH) test. HER2 positive BC patients were eligible
for inclusion as long as ER and PR were negative.
2.2. Data collection
We retrieved data on patient and tumor characteristics, BC
treatment and menstrual cycle from the medical files. For the pa-
tients in our cohort, reporting on menstrual cycle and menopausal
status was not standardized, but performed at the discretion of the
physician doing the follow-up. Patients reported to have persisting
menstruation during and after chemotherapy, and patients re-
ported to have had recovery of menstruation at any point during
follow-up were allocated to the group with recovery and persis-
tence of menstruation, for readability now referred to as the “re-
covery of menstruation” group. Women experiencing
chemotherapy-induced amenorrhea without any recovery during
follow-up were allocated to the group without recovery of
menstruation after chemotherapy. In the latter group, to prevent
misclassification of women who had a delayed recovery of
menstruation, an additional confirmation of postmenopausal sta-
tus at least 12 months after diagnosis was required for those pa-
tients younger than 45 years of age at BC diagnosis. For older
patients, considering the fact that recovery of menstruation afterchemotherapy-induced amenorrhea is very unlikely after 12
months, no additional confirmation was required [12].
2.3. Statistical analyses
We tested for differences between the two groups using the chi-
squared test for categorical variables and the Wilcoxon rank-sum
test for continuous variables. The primary endpoint of the study
was disease-free survival (DFS), defined as time at risk until first
loco-regional recurrence, distant metastasis, ipsilateral second
breast cancer or BC-related death (not preceded by known loco-
regional recurrence or distant metastasis). Overall survival (OS),
the secondary endpoint, was defined as time at risk until all-cause
death. The observation period started one year after BC diagnosis,
since recurrent disease within one year after BC diagnosis is un-
likely to be attributed to changes in hormonal status. Censoring
events for the DFS analyses were a new cancer diagnosis other than
ipsilateral BC (excepting incidental FIGO stage I ovarian cancer not
requiring chemotherapy, non-melanoma skin cancer and cervical
intra-epithelial neoplasia), death not related to BC, and date of last
follow-up. For the OS analyses, date of last follow-up was the only
censoring event. Due to the retrospective nature of this study, data
on course of menstruationwas missing for a substantial proportion
of the patients. To investigate whether exclusion of these patients
has led to selection bias, we compared both in- and excluded pa-
tients on the main factors of interest. To explore the effect of
different definitions of the DFS endpoint, we performed two
sensitivity analyses, one including contralateral second breast
cancers and the other excluding ipsilateral and contralateral second
breast cancers. An overview of all analyses is displayed in
Supplementary Table 1.
We used both stepwise inclusion and full multivariable Cox
proportional hazards models to calculate hazard ratios and
accompanying 95% confidence intervals (CI) for DFS and OS, using
the group without recovery of menstruation as the reference. Age,
known BRCA mutation (yes/no), tumor size, lymph node status,
neoadjuvant chemotherapy (yes/no), endocrine therapy (yes/no),
and risk-reducing salpingo-oophorectomy (RRSO) during the
observation period (yes/no, time-dependent) were considered as
potential confounders. For the stepwise model, we included a po-
tential confounder into the multivariable model if 1) there was a
significant difference between the two groups for the variable, 2)
the likelihood ratio test showed a significant difference between
the models with and without the variable, and 3) there was no
significant interaction of the variable with the main variable of
interest (i.e. recovery of menstruation yes or no). For each variable,
the proportional hazards assumption was inspected visually by
drawing a graph of log(-log(survival)) against log(survival time)
and tested formally using scaled Schoenfeld residuals.
We used STATA (version15.1, StataCorp, College Station TX, USA)
for all analyses. All p-values were two-sided and a significance level
a ¼ 0.05 was used.
3. Results
3.1. Study population
The patient selection procedure is summarized in a flow-
diagram (Fig. 1). For 397 patients out of 636 (62%), sufficient data
onmenstrual status was available in themedical files, of whom 299
patients (75%) had recovery of menstruation. Patients with recov-
ery of menstruation after chemotherapy were younger at BC diag-
nosis than patients without recovery of menstruation (median age
of 34.6 vs 43.7, p < 0.001), were more often without lymph node
involvement (55% vs 34%, p ¼ 0.001), and were less often treated
Fig. 1. Flow diagram of patient selection. Abbreviations: BC, breast cancer; ER, estrogen receptor; PR, progesterone receptor; CBC, contralateral breast cancer; DFS, disease-free
survival; OS, overall survival.
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of BRCA-mutation carriers was high in both groups (48% and 47% in
the group with and without recovery, respectively). Patients with
recovery of menstruation more often underwent prophylactic
mastectomy than patients without recovery (34% vs 20%,
p ¼ 0.013), but less often opted for RRSO (27% vs 43%, p ¼ 0.003)
(Table 1).
Comparing baseline characteristics between these included
patients (n ¼ 397) and the excluded patients (n ¼ 219) revealed
significant differences in median age at diagnosis (36.8 vs 40.0,
p < 0.001), HER2 positivity (19% vs 30%, p ¼ 0.007) and comple-
mentary treatment with trastuzumab (11% vs 17%, p ¼ 0.018). Morepatients in the excluded group received radiotherapy (71% vs 87%,
p < 0.001) (Supplementary Table S1).3.2. Disease-free survival
Among those patients who developed a BC related event, 22
patients experienced a loco-regional recurrence, 46 patients a
distant metastasis, seven patients an ipsilateral second primary
breast cancer and one patient died of BC without previous docu-
mentation of a recurrence (Table 2).
Recovery of menstruation after chemotherapy for BC was not
associated with an increased risk of recurrent disease in the
Table 1
Comparison of patient and tumor characteristics between recovery and no recovery ofmenstruation. Abbreviations: AI, aromatase-inhibitor; LHRH, luteinizing hormone-
releasing hormone; RRM, risk-reducing mastectomy; RRSO, risk-reducing salpingo-oophorectomy; NAC, neoadjuvant chemotherapy; AC, Doxorubicin (Adriamycin) þ
Cyclophosphamide; CMF, CyclophosphamideþMethotrexateþFluorouracil; FAC / FEC, Fluorouracil þ Doxorubicin/Epirubicin þ Cyclophosphamide.
Recovery of menstruation after chemotherapy
N¼ 299 (75%)
No recovery of menstruation after chemotherapy
N¼ 98 (25%)
p-value
Follow-up time in years, median (range) 6.2 (1.0 e 23.7) 8.1 (1.1 e 27.0) 0.0260
Age at diagnosis, median years (range) 34.5 (23.6 - 49.6) 43.6 (27.2 e 49.9) <0.001
Year of diagnosis, median (range) 2004 (1991-2014) 2003 (1990-2013) 0.0182
Year of diagnosis, 5-year categories 0.001
1990-1994 12 (4) 15 (15)
1995-1999 31 (10) 16 (16)
2000-2004 113 (38) 26 (27)
2005-2009 86 (29) 26 (27)
2010-2014 57 (19) 15 (15)
Proven BRCA mutation 0.743
No 156 (52) 53 (53)
Yes 143 (48) 45 (47)
BRCA1 134 (45) 37 (38)
BRCA2 9 (3) 7 (8)
BRCA1þBRCA2 0 1 (1)
Tumor size (pT/cT)a 0.592
1 130 (44) 38 (40)
2 137 (46) 45 (48)
3 16 (5) 8 (9)
4 15 (5) 3 (3)
Unknown 1 4b
Lymph-node status (pN/cN)a 0.001
0 163 (55) 33 (34)
1 88 (29) 41 (42)
2 31 (10) 10 (10)
3 17 (6) 14 (14)
Tumor grade 0.616
<3 28 (10) 7 (9)
3 250 (90) 78 (92)
Unknown 21 13
HER2 status 0.970
HER2þ 43 (18) 13 (19)
HER2- 191 (82) 57 (81)
Unknown 65 28
Type of surgery 0.022
No surgery 0 2 (2)
Lumpectomy 165 (55) 46 (47)
Mastectomy 134 (45) 50 (51)
Radiotherapy received 209 (70) 73 (74) 0.572
Endocrine therapyc 9 (3) 14 (14) <0.001
Tamoxifen 45 (44) 9 (75)
Tamoxifen þ AI 1 (11) 0
Tamoxifen þ LHRH-analogue 1 (11) 1 (8)
LHRH-analogue alone 3 (33) 2 (17)
Targeted therapy 32 (11) 9 (9) 0.668
RRM 101 (34) 20 (20) 0.013
RRSO 80 (27) 42 (43) 0.003
Chemotherapy 299 98
Of whom NAC 32 (11) 13 (13) 0.487
Chemotherapy regimen 0.004
AC 110 (37) 28 (29)
CMF 11 (4) 14 (14)
FAC / FEC 72 (24) 24 (24)
Taxane-containing 83 (28) 27 (28)
Other / Unknown 23 (7) 5 (5)
Eleven patients were not included in the disease-free survival (DFS) analysis because of a DFS-related event or censoring event before the start of observation (i.e. one year
after breast cancer diagnosis). Therefore, 397 patients were eligible for overall survival (OS) analysis and 386 were eligible for DFS analysis.
a For patients who were treated with neoadjuvant chemotherapy, the clinical stage is reported.
b Three out of these four patients with an unknown tumor size were reported to have occult breast cancer, with pathologically proven adenocarcinoma metastasis in the
axilla.
c Reasons for patients receiving endocrine therapy were the following: tamoxifen as primary adjuvant treatment as part of the EORTC 10901 trial (n¼10); tamoxifen for
unknown reasons (n¼2); tamoxifen (n¼1) and tamoxifenþLHRH-analogue (n¼1) as a result of a false positive progesterone receptor test; tamoxifenþAI (n¼1) and
tamoxifenþLHRH-analogue (n¼1) for an ER/PR of 1-9%; LHRH-analogue during chemotherapy to protect the ovaries (n¼1); LHRH-analogue to suppress a recovery of
menstruation (n¼1); LHRH-analogue for unknown reasons (n¼2). For two patients, we could not find what specific endocrine therapy was prescribed nor the reason for it.
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Fig. 2A). After adjusting for lymph-node status only (in a stepwise
model) or other relevant variables (full multivariable model) therecovery of menstruation was associated with a non-significant
higher risk of recurrent disease, showing an HR of 1.45 (95% CI:
0.83e2.54) for the stepwise model and an HR of 1.31 (95% CI:
Table 2
Comparison of disease-free and overall survival endpoints between recovery and no recovery of menstruation groups. Abbreviations: BC, breast cancer.
Disease-free survival endpoints (main analysis): Recovery of menstruation No recovery of menstruation
N¼294 N¼92
Number (%) Number (%)
Loco-regional recurrence only 17 (6) 5 (5)
Distant metastases 36 (12) 10 (11)
2nd primary ipsilateral BC 6 (2) 1 (1)
BC-related death 1 (0) 0
Overall survival endpoints (main analysis): Recovery of menstruation No recovery of menstruation
N¼299 N¼98
Number (%) Number (%)
Total deaths 61 (20) 22 (22)
Causes:
Breast cancer 56 (19) 21 (21)
Ovarian cancer 1 (0) 0
Lung cancer 1 (0) 1 (1)
Unknown cause 3 (1) 0
Table 3
Hazard ratios from univariable and multivariable Cox proportional hazards models for main analyses of DFS and OS. Abbreviations: DFS, disease-free survival; OS, overall
survival; HR, hazard ratio; ref, reference group; RRSO, risk-reducing salpingo-oophorectomy.
DFS OS
Univariable
HR (95% CI)
HR in stepwise
multivariable model (95%
CI)a
HR in full multivariable
model (95% CI)z
Univariable
HR (95% CI)
HR in stepwise
multivariable model (95%
CI)a
HR in full multivariable
model (95% CI)z
Recovery vs. no recovery
of menstruation
1.24 (0.71
e2.15)
1.45 (0.83e2.54) 1.31 (0.66e2.59) 1.07 (0.66
e1.76)
1.19 (0.71e1.98) 0.98 (0.51e1.88)
Age at diagnosis,
continuous
1.00 (0.97
e1.04)
0.99 (0.95e1.04) 1.00 (0.97
e1.04)
0.98 (0.93e1.02)
Untested or no BRCA
mutation
1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
BRCA1 mutation 0.58 (0.36
e0.94)
0.62 (0.36e1.09) 0.43 (0.27
e0.69)
0.50 (0.28e0.90)
BRCA2 mutation 1.11 (0.44
e2.79)
1.24 (0.45e3.41) 0.55 (0.17
e1.76)
0.72 (0.21e2.47)
Tumor size (pT/cN)
1 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
2 2.29 (1.36
e3.87)
2.11 (1.24e3.59) 1.77 (1.07
e2.94)
1.65 (0.99e2.78)
3 2.57 (1.03
e6.36)
1.34 (0.48e3.72) 3.61 (1.72
e7.56)
1.99 (0.86e4.59)
4 4.07 (1.64
e10.1)
1.89 (0.62e5.81) 4.49 (2.01
e10.0)
2.01 (0.73e5.57)
Lymph node status (pN/
cN)
0 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
1 1.59 (0.94
e2.68)
1.66 (0.98e2.80) 1.44 (0.84e2.49) 2.03 (1.21
e3.42)
2.11 (1.25e3.56) 1.66 (0.96e2.89)
2 1.73 (0.84
e3.57)
1.79 (0.87e3.69) 1.76 (0.83e3.72) 2.32 (1.20
e4.50)
2.87 (1.47e5.59) 2.39 (1.20e4.76)
3 2.87 (1.40
e5.92)
3.16 (1.52e6.59) 2.83 (1.27e6.27) 2.59 (1.24
e5.41)
3.11 (1.47e6.60) 2.25 (1.02e4.94)
Neoadjuvant
chemotherapy, yes vs
no
2.12 (1.14
e3.94)
1.66 (0.77e3.64) 3.10 (1.83
e5.25)
1.74 (0.86e3.51)
Endocrine therapy, yes vs
no
0.64 (0.20
e2.03)
0.55 (0.17e1.82) 0.40 (0.12
e1.29)
0.30 (0.09e0.99) 0.28 (0.08e1.00)
RRSO, yes vs no, time-
dependent
1.02 (0.48
e2.19)
1.63 (0.68e3.90) 0.52 (0.25
e1.06)
1.04 (0.45e2.40)
a Multivariable hazard ratio is for the model constructed using the forward stepwise process described in the Methods section. z The full model includes all clinically
relevant variables, regardless of statistical significance (age, tumor size, lymph node status, BRCAmutation, RRSO as time-dependent variable, neoadjuvant therapy, endocrine
therapy).
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Fig. 2. A. Disease-free survival curves based on the cox proportional hazards model,
adjusted for lymph node status. B. Overall survival curves based on the cox propor-
tional hazards model, adjusted for lymph node status and endocrine therapy.
M. van Barele et al. / The Breast 52 (2020) 102e109 1070.66e2.59) for the full model (Table 3).
3.3. Overall survival
The OS analysis included eleven more patients who were
censored in the DFS analysis because of a DFS-related, but not OS-
related (censoring) event prior to the start of the observation
period. Recovery of menstruation after chemotherapy was not
associated with OS in univariable analysis (hazard ratio 1.07, 95% CI
0.66e1.76; Table 3, Fig. 2B). After adjusting for lymph-node status
and endocrine therapy (in a stepwise model) or other relevant
variables (full multivariable model) recovery of menstruation was
not associated with a higher risk of death, showing an HR of 1.19
(95% CI: 0.71e1.98) for the stepwise model and an HR of 0.98 (95%
CI: 0.51e1.88) for the full model (Table 3).
3.4. Additional analyses
Considering the variety of DFS definitions, two sensitivity ana-
lyses were performed with differing endpoints for DFS (including
or excluding ipsilateral and contralateral second primary breast
cancer), in which similar results were found (Supplementary
Table 1).
To determine the presence of a potential selection bias, we used
Cox proportional hazards models to compare the survival of all
included patients with that of the excluded patients. We foundsimilar a DFS for the excluded group (full model HR: 0.88, 95% CI
0.57e1.35), but a trend for worse overall survival for the excluded
group (full model HR: 1.35, 95% CI 0.94e1.93).
4. Discussion
Our results showed that recovery of menstruation after
chemotherapy did not have a significant effect on the risk of
recurrent disease or mortality in young patients with hormone
receptor-negative BC. While consistent with the idea that, from a
clinical viewpoint, hormone exposure should not impact survival in
hormone receptor-negative BC, the multivariable models are not
particularly reassuring. The hazard ratio of 1.45 found in the
multivariable DFS model, although not significant, raises the
concern that a deleterious effect of hormone exposure in hormone
receptor-negative BC patients cannot be excluded.
Our findings appear to be in contrast with previous studies
investigating the impact of recovery of ovarian function after
chemotherapy in BC patients, as demonstrated in a meta-analysis
by Zhou et al. [13]. In their hormone receptor-negative subgroup
analysis of three studies, they show no difference in survival be-
tween recovery and absence of ovarian activity after chemotherapy
(HR 0.97, 95% CI: 0.66e1.41). One of the most recent studies con-
cerning the prognostic effect of chemotherapy-induced amenor-
rhea in HR-negative BC patients did not find a difference in survival
either [14].
A possible explanation for the discrepancy of our result could be
the differences in how hormonal exposures were defined. Most
previous studies used a certain period (usually three or six months)
of absence of menstruation (amenorrhea) after chemotherapy, to
define the absence of hormonal exposure [15]. This definition leads
to classifying any woman with menstruation recovering after this
specific period being classified as not having hormonal exposure.
This misclassification increases the risk in the hormonally non-
exposed group if an increased risk from hormone exposure does
indeed exist. As a result, this mixing of exposures artificially lowers
the risk ratio for hormone exposure (as both groups will now have
an increased risk). The only other study using a similar definition
for ovarian activity as we did, with a median duration of FU of 6.2
years, was not included in the meta-analysis by Zhou et al., 2015
[13]. This study showed a trend towards worse DFS for the sub-
group of hormone receptor-negative BC patients with recovery of
menstruation after chemotherapy (HR 1.73, 95% CI 0.86e3.48) [16].
Combining this result with ours in a pooled analysis yields an HR of
1.55 (95% CI 1.00e2.40), suggesting that the statistical non-
significance of our primary result may be due to insufficient po-
wer (Supplementary Fig. 1). This further strengthens our concern
that a potentially increased recurrence risk fromhormone exposure
by means of recovered menstruation, cannot be excluded.
Our definition of hormone receptor-negative breast cancer us-
ing <10% expression of ER and PR on immunohistochemistry, may
have affected our results. Previous studies have shown that from a
clinical point of view, tumors with 1e9% receptor expression often
behave like triple negative tumors as far as endocrine sensitivity is
concerned. In these studies, no benefit of adjuvant endocrine
therapy in the population with hormone receptor expression be-
tween 1 and 9% was found, similar to hormone receptor expression
less than 1% [17,18]. Therefore, it is our opinion that the inclusion of
patients with 1e9% ER/PR expression cannot explain the relatively
high adjusted HRs of e.g. 1.45 for DFS in our study.
There may be biological explanations for a potential risk of
hormonal exposure in hormone-receptor negative BC patients. One
potential mechanism through which female steroidal hormones
can act upon ER/PR-negative (tumor) cells is via Receptor Activator
of Nuclear factor Kappa(k)-B (RANK) and its ligand, RANKL. In short,
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RANKL when progesterone binds the PR receptor [19,20]. RANKL in
turn, is capable of stimulating proliferation in neighboring ER/PR-
negative cancer cells in a paracrine fashion by binding to the
RANK receptor on these cancer cells [21,22]. Interestingly, in a study
randomizing ER/PR-negative BC patients to either chemotherapy or
chemotherapy with goserelin (a LHRH-analogue), those in the
goserelin arm had a better overall survival as well as higher rates of
recovery of menstruation and pregnancy [23]. A recent meta-
analysis of this and several other studies on LHRH-analogue use
shows that the survival benefit in ER-negative BC patients largely
remains, although no longer statistically significant (HR 0.65; 95%
CI 0.39e1.07) [24]. While this is no definitive proof, it illustrates
that endocrine effects do appear to be present in hormone
receptor-negative BC patients. Another potential mechanism could
be endocrine activity via the ERb receptor, which is not routinely
tested for when determining the ER/PR status of a breast tumor.
Interestingly, in one study 70% of the 105 ERa-negative patients in
the cohort were ERb-positive (weak and strong immunohisto-
chemistry staining combined) [25], whereas another found ERb-
positivity in as much as 60% of ERa-negative cases [26]. The exact
role of ERb in ER-negative BC however, is not yet completely
understood.
To the best of our knowledge, our study is unique in that it is the
first to specifically look into the effects of hormone exposure in
hormone receptor negative BC, with a fairly large study population.
A potential weakness of our study is that data on menstrual cycle
status were not always recorded in the medical file, resulting in the
exclusion of a large group of patients of whommenopausal status is
unknown (34%). Apart from age, BRCA mutations and HER2 posi-
tivity with complementary targeted treatment, the excluded group
did not differ much from our included populationwhen comparing
baseline characteristics (Supplementary Table S2). Because the
excluded group represents a fairly large proportion of our initial
patients, we compared survival of those patients included with
survival of those left out of the study, showing a worse overall
survival for the excluded patients (Supplementary Fig. 2). Physi-
cians most likely have omitted questions about recovery of
menstruation among those patients with an early recurrence due to
focus on more important issues to discuss at such moments, lead-
ing to a skewed distribution of patients with poor prognosis to-
wards the excluded group. A sensitivity analysis where the
excluded patients are added to the group with recovery of
menstruation shows a further increase of risk associated with re-
covery of menstruation.When added to the non-recovery group, no
more negative effect of recovery of menstruation on mortality is
seen. However, it is unlikely that all these excluded patients would
have ended up in the group without recovery of menstruation, as
the median agewas forty (Supplementary Table S2) and recovery of
menstruation is therefore expected in the majority of patients.
Furthermore, in the study by Park and colleagues menstrual cycle
status was recorded at each visit to the outpatient clinic during
follow-up. This prospective gathering of data on menstrual cycle
status makes it unlikely that selection bias as described above could
have occurred, yet their results are very similar to ours [16].
In conclusion, although recovery of menstruation after chemo-
therapy did not have a significant effect on the risk of recurrent
disease or mortality in young hormone receptor-negative BC pa-
tients, the multivariable analyses were not particularly reassuring.
Although HRT does not function exactly as endogenous hormones,
and risks may therefore differ, we argue that prescribing HRT to
hormone receptor-negative BC patients suffering frommenopausal
complaints should not be considered lightly, and perhaps non-
hormonal treatment options should be explored first. Further
research on the safety of hormones and/or HRT in young hormonereceptor-negative BC patients is clearly warranted.
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